FDA Approved: MAVYRET — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

The FDA approved a supplemental application for MAVYRET (glecaprevir and pibrentasvir) submitted by AbbVie.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Mavyret (glecaprevir/pibrentasvir)

Snippet

SUPPL AP for MAVYRET (GLECAPREVIR AND PIBRENTASVIR)